Dyne Therapeutics is a clinical-stage biopharmaceutical company developing treatments for genetically driven neuromuscular diseases. Dyne's core technology is its proprietary FORCE platform, which delivers therapeutic payloads — such as oligonucleotides or enzymes — directly to muscle tissue by attaching them to a Fab antibody fragment that binds to transferrin receptor 1 (TfR1), a protein highly expressed on muscle cell surfaces. When the Fab binds TfR1, the cell internalizes it, delivering the payload inside. Dyne argues this targeted approach achieves far greater muscle uptake than current "naked" (unconjugated) oligonucleotide therapies. Dyne's two lead programs are z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy, which uses a PMO payload to promote exon 51 skipping and enable production of functional dystrophin, and z-basivarsen (DYNE-101) for myotonic dystrophy type 1, which uses an ASO payload to degrade toxic DMPK RNA. Both are in Phase 1/2 trials, with BLA submissions targeting 2026 and 2027, respectively, via FDA Accelerated Approval pathways. Beyond these, Dyne has preclinical programs in facioscapulohumeral dystrophy and Pompe disease, plus a DMD franchise expansion targeting additional exon-skipping candidates. Dyne retains global commercial rights to all programs. Dyne is pre-revenue and funds operations through equity financing, with a business model built around selling high-priced drugs to small, well-characterized rare disease patient populations using a lean specialty sales force.